Liraglutide could reduce monthly migraine days
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Canada can learn from England’s successful diabetes prevention program to build its own programs to tackle diabetes prevention across the country, argue authors in an analysis in CMAJ (Canadian Medical Association… read more.
Amgen announced full results from Part 1 of the Phase II study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type… read more.
A new study from the University of Colorado Anschutz Medical Campus shows that primary care clinics can successfully help patients start using continuous glucose monitors (CGMs), which track blood sugar… read more.
An intensive low-energy diet programme, similar to the NHS Type 2 Diabetes Path to Remission, significantly improved eating disorder symptoms in people with type 2 diabetes and excess weight who… read more.
What do chickens and people with a common reproductive disorder have in common? More than one might think — and a widely-used diabetes medication might just be the… read more.
Abbott, a global leader in continuous glucose monitoring (CGM) biowearable technology announced that it has entered a first-of-its-kind agreement to integrate data from its leadiing Libre CGM systems… read more.
BioMarin Pharmaceutical Inc. announced new data from studies of Voxzogo (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal… read more.
Medtronic plc announced it has submitted 510(k) applications to the FDA seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration… read more.
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has… read more.
A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the… read more.
Novo Nordisk presented the full results from STRIDE, a phase III peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic (semaglutide 1.0 mg) in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.